Key Abstracts in HER2-Positive Breast Cancer From SABCS 2023 Key Abstracts in HER2-Positive Breast Cancer From SABCS 2023

Highlights in HER2+ breast cancer from SABCS 2023 include data from the HER2CLIMB-02 trial of tucatinib plus T-DM1 and a 9-year follow-up of the KATHERINE trial, as discussed by Dr Harold Burstein.Medscape
Source: Medscape Today Headlines - Category: Consumer Health News Tags: None ReCAP Source Type: news